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ABSTRACT 
The colon is a site where both local and systemic delivery of drugs can take place. The colon targeted drug delivery system is used 
for the treatment of various diseases related to colon like Crohn’s disease, ulcerative colitis, etc and systemic delivery of 
therapeutic peptides and proteins. It can be possible to target disease site thus lowers the requirement of higher doses of drug and 
reducing the dosage frequency and cost of the drugs. It also lowers the systemic side effects.  
For successful colon targeted drug delivery, a drug needs to be protected from degradation, release and absorption in the upper 
portion of the gastric intestinal tract and then to be ensured abrupt or controlled release in the proximal colon.  
This article gives detail description on anatomy and physiology of the colon and approaches utilized for colon specific drug 
delivery like prodrugs, pH and time dependent, prodrug, osmotic pressure controlled drug delivery. 
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INTRODUCTION 
Since the past decades research is going on in 
developing the methods to deliver therapeutic amount 
of drug to the specific organ so that the desired 
concentration can be achieved swiftly and then 
maintained
1
.  
Colon targeted drug delivery is used to deliver the 
substances that are polar and degraded by the digestive 
enzymes in the gastrointestinal tract. Proteins and 
peptides such as insulin, calcitonin and vasopressin, 
cytokine inhibitors and antibiotics may be delivered 
systematically via colonic absorption. Anti-asthmatic 
drugs, antihypertensive drugs and anti-diabetic agents 
can also be delivered systemically
2
. 
 It is also used for the treatment of various diseases like 
ulcerative colitis, Crohn’s disease, intestinal cancer, 
diarrhea, for the treatment of diseases sensitive to 
circadian rhythms like asthma, angina, for the delivery 
of steroids, etc
3
.  
Colon targeted drug delivery system increases the 
absorption of poorly absorbable drugs due to the high 
retention time of the colon. Formulations for colonic 
delivery are also suitable for delivery of drugs which 
are susceptible to chemical and enzymatic degradation 
in the upper GI tract, highly affected by hepatic 
metabolism, in particular, therapeutic proteins and 
peptides
4
. 
Advantages: Colon-specific drug delivery system 
offers the following therapeutic advantages- 
1. Reduction of the adverse effects during the 
treatment of colonic diseases i.e. ulcerative 
colitis, colorectal cancer, Crohn’s disease etc. 
2. Avoidance of first pass metabolism of steroids. 
3. Prevention of the gastric irritation produced after 
oral administration of NSAIDS
5
.  
4. Delayed release of drugs in treatment of diseases 
i.e. angina, asthma and rheumatoid arthritis. 
5. Decreased frequency of drug administration, 
increased patient compliance
6
. 
6. Provides suitable environment for proteins and 
peptides that are sensitive to gastric fluid and 
digestive enzymes
7
. 
7. Increase bioavailability of poorly absorbable 
drugs
8
. 
Limitations 
1. Multiple manufacturing steps. 
2. Incomplete release of drug. 
3. Bioavailability of drug may be low due to 
potentially binding of drug with dietary residues, 
intestinal secretions, mucus or fecal matter
9
. 
4. The resident microflora may affect colonic 
performance through metabolic degradation of 
the drug. 
5. Non availability of a suitable dissolution testing 
method to evaluate the dosage form in-. 
6. It is necessary that drug should be in solution 
form before absorption and there for rate limiting 
step for poor soluble drugs
10
.   
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Anatomy of colon 
The GIT consists of parts from mouth to anus. It 
mainly consists of stomach, small intestine and large 
intestine. The GIT measures about 5 meters long. The 
different parts of GIT are divided into upper and lower 
gastrointestinal tract. The upper GIT includes 
oesophagus, stomach, and duodenum. The lower GIT 
includes small intestine and large intestine
11
. 
 The large intestine extending from the ileocecal 
junction to the anus is divided in to three main parts. 
These are the colon, the rectum and anal canal. Colon 
is about 5 feet (150 cm) long, and is divided in to five 
major segments. The entire peritoneal folds called as 
mesentery, supported by ascending and descending 
colon. The right colon consists of the cecum, ascending 
colon, hepatic flexure and the right half of the 
transverse colon
12
. The left colon contain the left half 
of the transverse colon, descending colon, splenic 
flexure and sigmoid. 
Figure 1: Anatomy of colon 
Criteria for selection of drug for colonic drug delivery 
drug candidate
13, 14, 15
-  
1. It should poorly absorb form stomach and small 
intestine e.g. peptides. 
2. It should be compatible with carrier molecule and 
easily biotransform in large intestine. 
3. It should be stable at alkaline pH of GIT. 
4. It should have both local and systemic effects. 
5. Drug use in treatment of various intestinal 
disorders such as ulcerative colitis, amoebiasis 
and colon cancer, inflammatory bowel disease, 
diarrhea are ideal candidates for local colon 
delivery e.g. sulfasalazine, olsalazine, 
mesalazine, steroids like fludrocortisone, 
budesonide, prednisolone and dexamethasone. 
 
FACTORS AFFECTING COLON TARGETED 
DRUG DELIVERY 
1. Physiological factors 
2. Pharmaceutical factors 
1. Physiological factors 
a. Gastric emptying 
Drug delivery to the colon upon oral administration 
depends mainly on gastric emptying and bowel transit 
time. Upon reaching the colon the transit time of 
dosage form depends on the size of the particles. 
Smaller particles have more transit time compared to 
larger particles. Diarrhoea patients have shorter transit 
time whereas constipation patients have longer transit 
times
16
. 
b. pH of colon 
The pH of GIT varies between different individuals. 
The food intake, diseased state, etc. influences the pH 
of the GIT. This change in the pH in different parts of 
GIT is the basis for the development of colon targeted 
drug delivery systems. Coating with different polymers 
is done to target the drug to the site
17
. 
c. Colonic microflora and enzymes 
The GIT contains a variety of microorganisms that 
produces many enzymes need for metabolism. Growth 
of this microflora is controlled by the GIT contents and 
peristaltic movements. The enzymes released by 
different microorganisms E. coli, Clostridia, 
Lactobacilli, 
Eubacteria, Streptococci are responsible for the various 
metabolic reactions that take place in 
the GIT
18
. 
2. Pharmaceutical factors 
a. Drug candidates: 
Due to high retention time of colon, colon causes an 
increase in the absorption of poorly 
b. Drug carriers: 
The selection of carrier for CDDS depends on the 
nature of the drug, disease for which the drug is used. 
The various physicochemical factors of drug that effect 
the carrier selection includes chemical nature, stability, 
partition coefficient, functional groups of drug 
molecule
19
. 
 
APPROACHES FOR THE DEVELOPMENT OF 
COLON TARGETED DRUG DELIVERY 
Chemical or Prodrug Approach  
A prodrug is a medication or compound that, after 
administration, is metabolized (i.e., converted within 
the body) into a pharmacologically active drug. 
 In this method, the prodrugs are designed to undergo 
minimum absorption and hydrolysis in the upper GIT 
and undergo enzymatic hydrolysis in the colon, there 
by releasing the active drug moiety from the carrier
20
.  
1. Azo bond conjugate  
In this approach the drug is attached via an azo bond to 
a carrier. Azo compounds are metabolized by the 
intestinal bacteria, both by intracellular enzymatic 
component and extracellular reduction. This azo bond 
is stable in the upper GIT and is cleaved in the colon 
by the azo-reductases produced by the microflora. The 
use of these azo compounds for colon-targeting has 
been in the form of hydrogels as a coating material for 
coating the drug cores and as prodrug
21
.  
2. Cyclodextrin conjugate  
Cyclodextrin is non toxic and bulky molecule; it has 
limited absorption from the GIT hence it is used as the 
carrier for some drug which are unstable in stomach 
and intestinal environment. Cyclodextrins are cyclic 
oligosaccharides consisted of six to eight glucose units 
through -1, 4 glucosidic bonds and have been utilized 
to improve certain properties of drugs such as 
solubility, stability and bioavailability
22
.  
Interior of these molecules is relatively lipophilic and 
the exterior relatively hydrophilic, form inclusion 
complexes with various drug molecules. After oral 
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administration, cyclodextrin form of biphinayl acetic 
acid were selectively reach in to the colon and release 
drug without absorb form upper GIT
23
. 
3. Glycoside conjugation  
Some drugs can be conjugated to different sugar 
moieties to form glycosides. The drug part forms the 
aglycone and is linked to the sugar part, which forms 
the glycone part of the glycoside. Because they are 
bulky and hydrophilic, these glycosides do not 
penetrate the biological membranes upon ingestion. 
Enzyme glycosidases produce by various human 
microflora are β-D-galactosidase, α-Larabino 
furanosidase and β –D glucosidase. Steroid glycosides 
and the unique glycosidase activity of the colonic 
microflora form the basis of a new colon targeted drug 
delivery system. Glycosides are hydrophilic and poorly 
absorb from GIT because of this properties it use as the 
carrier for delivering drug to colon. Drug targeted by 
this approach are lucosides, galactosides, and 
cellobiosides of dexamethasone, prednisolone, 
hydrocortisone, and fludrocortisone
24
. 
4. Glucoronide conjugates  
Glucuronide conjugation is the major metabolic 
pathway of drug. Bacteria present in lower GIT secrete 
β-glucuronidase and can deglucuronidate a variety of 
drugs in the intestine.  Thus, the deglucuronidation 
process results in the release of the active drug again 
and enables its reabsorption. This concept is used to 
deliver drug to colon, where drug is couple with 
glucuronid conjugation after oral delivery
25
. 
5. Dextran conjugate  
Dextran prodrug approach can be used for colon-
specific delivery of drugs containing a carboxylic acid 
function. Dextran is the carbohydrate and colonic flora 
use it as the energy source. Dextrans are 
polysaccharides of bacterial origin where the 
monosaccharides are joined to each other by glycoside 
linkages. Dextranase enzymes are responsible for the 
hydrolysis of these linkages. In the colon, dextran’s 
glycosidic bonds are hydrolyzed by dextranases to give 
shorter prodrug oligomers, which are further split by 
the colonic esterases to release the drug free in the 
lumen of the colon
26
.  
6. Amino acid conjugation 
Polar groups like -NH2 and –COOH are hydrophilic in 
nature and are present in the proteins and their basic 
units (i.e. the amino acids). They reduce the membrane 
permeability of amino acids and proteins. Increase in 
hydrophilicity and chain length of carrier amino acid; 
decrease the permeability of amino acids and proteins. 
Thus the amino acid conjugate are more enzymatic 
specificity for hydrolysis by colonic enzymes
27
.  
7. Polymeric prodrugs: In newer approaches, 
polymers are used as drug carriers to deliver it, to the 
colon. Both synthetic as well as naturally occurring 
polymers are used for this purpose
28
.  
Pharmaceutical approach 
1. Coating of the drug core with pH sensitive 
polymers:  
Drug molecule can be coated with the suitable 
polymers, which degrade only in the colon. In this way 
the intact drug molecule can be delivered to the colon 
without absorbing at the upper part of the intestine. The 
drug core includes tablets, capsules, pellets, granules, 
microparticles or nanoparticles. The use of pH-
sensitive polymers to the tablets, capsules or pellets 
provide delayed release and protect the active drug 
from gastric fluid
29
.  
The limitation of this approach is that the intestinal pH 
is not stable because it is affected by diet, disease and 
presence of fatty acids, carbon dioxide, and other 
fermentation products.  
2. Time dependent delivery 
 
 
Figure 2: Time-controlled capsule for colonic 
delivery 
It also known as pulsatile release, delayed or sigmoidal 
release system. In this approach, drug release from the 
system after a predetermined lag time according to 
transit time from mouth to colon.  
It is based on the concept of preventing the release of 
drug 3–5hr after entering into small intestine i.e. 
delaying the release of the drug until it enters into the 
colon
30
.  
These systems consist of a non disintegrating half 
capsule body sealed at the open end with a hydrogel 
plug, covered by a water-soluble cap. The entire unit is 
coated with an enteric polymer to avoid the problem of 
variable gastric emptying. When the capsule enters the 
small intestine, the enteric coating dissolves and the 
hydrogel plug starts to swell. 
These systems are therefore particularly useful in the 
therapy of diseases, which depend on circadian 
rhythms
31
.  
3. Bioadhesive systems  
Bioadhesion is a process by which a dosage form 
remains in contact with particular organ for a specific 
period of time.  This longer residence time of drug 
would have high local concentration or improved 
absorption characteristics in case of poorly absorbable 
drugs. Polycarbophils, polyurethanes and polyethylene 
oxide-polypropylene oxide copolymers are used as 
materials for bioadhesive systems
32
. 
4. Multiparticulate systems 
The various multiparticulate approaches include 
pellets, microparticles, granules and nanoparticles are 
used as drug carriers in pH-sensitive, time dependent 
and microbially control systems for colon targeting. 
Multiparticulate systems enabled the drug to reach the 
colon quickly and were retained in the ascending colon 
for a relatively long period of time and hence increased 
bioavailability. Because of their smaller particle  
size as compared to single unit dosage forms these 
systems are capable of passing through the GI tract 
easily, leading to less inter- and intra subject 
variability
33
.  
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Limitations associated with single unit colon targeted 
drug delivery system can be avoided like unintentional 
disintegration of the formulation due to manufacturing 
deficiency or unusual gastric physiology that may lead 
to drastically compromised systemic drug 
bioavailability or loss of local therapeutic action in the 
colon.  
5. Osmotic controlled drug delivery  
This system consists of osmotic units either singly or as 
many as 5-6 push pull units that are encapsulated in a 
hard gelatin capsule. The push pull units are bilayered 
with outer enteric impermeable membrane and inner 
semi permeable membrane. In principle semipermeable 
membrane is permeable to the inward entry of water 
and aqueous gastrointestinal fluids and is impermeable 
to the outward exit of the drug
34
. Whenever water 
enters the unit causing the osmotic push compartment 
to swell forcing the drug out of the orifice into colon. 
 
EVALUATION OF CDDS 
1. In-vitro evaluation: Different in vitro  methods are 
used to evaluate the colonic drug delivery systems. In 
in- vitro studies the ability of the coats/carriers to 
remain intact in the physiological environment of the 
stomach and small intestine is assessed by drug release 
studies in 0.1N HCl for two hours (mean gastric 
emptying time) and in pH 7.4 phosphate buffer for 
three hours (mean small intestine transit time) using 
USP dissolution apparatus. The amount of drug 
released at different time intervals during the 
incubation is estimated to find out the degradation of 
the carrier under study
35
.  
The dissolution testing is done using the conventional 
basket method. The dissolution testing is done in 
different buffers to check the behavior of formulations 
at different pH levels. Dissolution tests of a colon-
specific formulation in various media simulating pH 
conditions and times likely to be encountered at 
various locations in the gastrointestinal tract  The 
different media that are used for the dissolution testing 
of colon targeted drug delivery are pH 1.2 to simulate 
gastric fluid, pH 6.8 to simulate small intestine, pH 7.4 
to simulate large intestine. Formulations are tested for 
2 hr in 0.1N HCl, 3hr in pH 6.8 phosphate buffer and 
finally at pH 7.4 phosphate buffer. Buffers of the above 
pH are prepared to evaluate the colon targeted drug 
delivery systems
36
. 
2. Enzymatic test 
There are 2 tests- 
i. The carrier drug system is incubated in fermenter 
containing suitable medium for bacteria. The amount 
of drug released at different time intervals is 
determined. 
ii. Drug release study is performed in buffer medium 
containing enzymes pectinase, dextranase or rat or 
guinea pig or rabbit cecal contents. The amount of drug 
released in a particular time is directly proportional to 
rate of degradation of polymer carrier
37
. 
3. In-vivo evaluation 
The in-vivo evaluation of the CDDS is done in dogs, 
guinea pigs, rats and pigs as they resemble the 
anatomic and physiological conditions, micro flora of 
human GIT. The distribution of various enzymes in 
GIT of rat and rabbit is comparable to that in human
38
. 
 
CONCLUSION 
Colon targeted drug delivery system offers benefits of 
local and systemic effects. The main advantage of 
CDDS is that reduced incidence of systemic side 
effects, lower dose of drug, supply of the drug only 
when it is required and maintenance of the drug in its 
intact form as close as possible to the target site. Colon 
offers near neutral pH, a long transit time, reduced 
enzymatic activity and increased responsiveness to 
absorption enhancers.  
The novel approaches are more specific compared to 
the primary approaches. The biodegradable polymers 
are used for the colon specific delivery of the drug. 
These systems provide friendlier environment for 
protein and peptide drugs that reducing the adverse 
effects in the treatment of colonic diseases, site specific 
release to treat colonic cancer, amoebiasis, and 
helminthiasis etc, minimizing the extensive first pass 
metabolism of steroids and produces delay in 
absorption of drugs to treat rheumatoid arthritis, angina 
and nocturnal asthma etc. 
For the in vitro evaluation of the system the current 
dissolution techniques are not suitable. Research is 
going on to develop suitable dissolution methods to 
evaluate the colon targeted drug delivery systems. 
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